mobile background
Korean Cancer Study Group 
Webzine Vol.32  JUNE 2024 
mobile background
논문 발간현황 2023.10 - 2024.04 

▶ BR15-17 | PMID : 38104354 

Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial 

Eur J Cancer. 2024 Jan:197:113456.


▶ HN18-08 | PMID : 37246414 

A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas 

Cancer. 2023 Oct 1;129(19):2966-2974.



▶ LU19-04 | PMID : 37861993 

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) 

J Clin Oncol. 2023 Oct 20:JCO2301891. Online ahead of print.



▶ BR18-16 | PMID : 37890351 

Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) 

Eur J Cancer. 2023 Dec;195:113386. Epub 2023 Oct 14.



▶ UN14-13 | PMID : 37741071 

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13) 

Eur J Cancer. 2023 Nov;193:113312. Epub 2023 Aug 28.



▶ LU19-04 | PMID : 37861993 

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) 

J Clin Oncol. 2023 Oct 20:JCO2301891. Online ahead of print.



▶ HN15-16 | PMID : 37699162  

Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial 

J Clin Oncol. 2023 Sep 12;JCO2202786. Online ahead of print.



▶ HN15-16 | PMID : 37475136 

A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN 15-16 TRIUMPH Trial. 

Cancer Res Treat. 2023 Jul 20. Online ahead of print.



▶ GU18-18 | PMID : 37385153 

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. 

ESMO Open. 2023 Jun 27;8(4):101588. Online ahead of print.



▶ LY20-06 | PMID : 37357604 

Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06). 

Korean J Intern Med. 2023 Jun 26. Online ahead of print.